| |
Guided
Therapeutics, Inc. (OTCBB: GTHP) (OTCQB:
GTHP) is developing a rapid and painless testing
platform for the early detection of disease based on its
patented biophotonic technology that utilizes light to
detect disease at the cellular level. The company’s
first planned product is the LuViva® Advanced Cervical
Scan, a non-invasive device used to detect cervical
disease instantly and at the point of care. In a
multi-center clinical trial, with women at risk for
cervical disease, the technology was able to detect
cervical cancer up to two years earlier than
conventional modalities, according to published reports.
Guided Therapeutics has also entered into a partnership
with Konica Minolta to develop a non-invasive test
for Barrett’s Esophagus using the technology platform.
3Q
Conference Call Webcast link. November 14, 11 a.m.
EST
Analyst Following Guided Therapeutics
Debjit Chattopadhyay, Ph.D., MBA
Emerging Growth Equities, Ltd.
1150 First Avenue, Suite 600
King of Prussia, PA 19406
Phone: 610.783.4782
Fax: 610.783.4761
Email: debjit@egequities.com
“Safe Harbor” Statement
under the Private Securities Litigation Reform Act of
1995. A number of the matters and subject areas
discussed in this web site that are not historical or
current facts deal with potential future circumstances
and developments. The discussion of such matters and
subject areas is qualified by the inherent risks and
uncertainties surrounding future expectations generally
and also may materially differ from Guided
Therapeutics’ actual future experience involving any of
or more of such matters and subject areas. Such risks
and uncertainties include: the early stage of products
in development, the uncertainty of market acceptance of
products, the uncertainty of development or
effectiveness of distribution channels, the intense
competition in the medical device industry, the
uncertainty of capital to develop products, the
uncertainty of regulatory approval of products,
dependence on licensed intellectual property, as well as
those that are more fully described from time to time
under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including
Guided Therapeutics’ Annual Report on Form 10-K for
the fiscal year ended December 31, 2011 and subsequent
quarterly reports. |
